FilingFirehose · free AI preview
Janux Therapeutics, Inc.
JANX · AI-generated SEC analysis preview · refreshes when data changes
⚠️ Red flag 8-Ks: 1
Types: Officer Departure
Janux Therapeutics (JANX) reported one officer departure in the past 90 days (filed April 28, 2026), with no cyber incidents detected during the same window. While a single departure doesn't indicate systemic distress, the biotech sector's sensitivity to leadership changes warrants deeper context on the role, replacement status, and board stability. The full $49 Report adds a dilution risk score spanning 12 months of financing activity, comprehensive 8-K analysis, AI-detected governance red flags, and historical comparison to peer departures in early-stage therapeutics.
Want the full 5-section $49 Report on JANX?
Dilution risk score · 12 months of 8-K context · financing history · AI risk signals · bottom-line framing. Delivered in ~5 minutes.
See a real sample report →
This preview was AI-generated from FilingFirehose's SEC EDGAR ingestion pipeline.
Not investment advice. Verify all claims against original filings.